Prognostic significance of C-reactive protein in unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab.
Kaneko S, Asahina Y, Murakawa M, Ueyama S, Maeyashiki C, Watanabe H, Kusano-Kitazume A, Sato A, Uchidate K, Asakawa T, Watanabe S, Iizuka Y, Shibata I, Oooka S, Karakama Y, Fujii T, Watabe T, Akahoshi K, Tanabe M, Inada K, Mochida T, Watakabe K, Shimizu T, Tsuchiya J, Miyoshi M, Kitahata-Kawai F, Nitta S, Nakagawa M, Kakinuma S, Okamoto R; Ochanomizu Liver Conference Study Group.
Kaneko S, et al. Among authors: asakawa t.
Hepatol Res. 2024 Jun;54(6):562-574. doi: 10.1111/hepr.14001. Epub 2024 Jan 11.
Hepatol Res. 2024.
PMID: 38133587